Whilst these treatments have transformed the prognosis for patients who are diagnosed with SMA, there is an ongoing need to understand the pathogenesis of SMA and gain a comprehensive understanding of what defects could persist or manifest later, even after treatment with an SMN upregulating therapy [5, 6]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.